FAIM
JAZZ icon

Financial Advocates Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Financial Advocates Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,277
Closed -$3.05M – 818
2022
Q3 		$3.05M Buy
+14,277
New +$2.17M 0.25% 105
2022
Q1 		– Sell
-13,854
Closed -$4.44M – 771
2021
Q4 		$4.44M Buy
+13,854
New +$1.82M 0.28% 89

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Financial Advocates Investment Management's JAZZ Position: Q4 2022 in Review

Financial Advocates Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2022, closing a stake of 14,277 shares — an estimated $3.05M sold.

Financial Advocates Investment Management first reported a position in JAZZ in Q4 2021 and held it in 2 quarters. The position peaked at $4.44M in Q4 2021. 487 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

  • Financial Advocates Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 14,277 Jazz Pharmaceuticals shares in Q4 2022, an estimated $3.05M.
  • Financial Advocates Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Financial Advocates Investment Management's Jazz Pharmaceuticals position peaked at $4.44M in Q4 2021.
  • 487 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on Financial Advocates Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.